

YEAR-END REPORT

2015/2016

Immunicum AB (publ), org. nr: 556629-1786

IMMUNICUM
DENDRITIC CELL-BASED IMMUNOTHERAPEUTICS

Summary of the

Year-End Report 2015/2016

Fourth quarter (April-June) in 2016 compared with the same period in 2015

- Operating profit/loss amounted to TSEK -15,068 (TSEK -8,230)
- Net profit/loss amounted to TSEK -15,018 (TSEK -7,804)
- Earnings per share before and after dilution (weighted average) amounted to SEK -0.74 (-0.39)

Financial year 2015/2016 compared with 2014/2015

- Operating profit/loss amounted to TSEK -43,643 (TSEK -36,404)
- Net profit/loss amounted to TSEK -43,923 (TSEK -35,615)
- Earnings per share before and after dilution (weighted average) amounted to SEK -2.18 (-1.78)
- Liquid funds and unit trust/mutual fund investments amounted to TSEK 129,442 (TSEK 68,165) at 30 June 2016.
- Shareholders' equity per share amounted to SEK 5.36 (3.23)
- Number of employees at the end of the period 8 (5)

Significant events during the 2015/2016 financial year

- On 9 November, the European Patent Office (EPO) provided notification that it intends to grant a patent based on the application pertaining to Immunicum's cancer immune activator, INTUVAX®. On 20 November, the Japanese Patent Office (JPO) announced that it intends to grant a corresponding patent application concerning INTUVAX.
- At the Annual General Meeting held in December, Magnus Persson was elected as a board member of Immunicum, where he replaces Sven Andréasson who had declined re-election.
- On December 16, the Swedish Medical Products Agency (MPA) and the Ethical Vetting Board gave the green light to launch the Company's fourth clinical trials, with the cancer immune activator INTUVAX. The clinical trial will be conducted on 12 patients with gastrointestinal stromal tumours (GIST) at the Karolinska University Hospital in Stockholm.
- On 16 December, the Swedish Medical Products Agency and the Ethical Vetting Board also gave its approval that the Phase I/II clinical trials concerning liver cancer may be expanded by up to six patients, who will receive INTUVAX in combination with first-line treatments.
- Immunicum's Scientific Advisory Board was further strengthened on 3 March with Anders Öhlén, who has extensive experience in the senior management level within pharmaceutical development from Kabi Pharmacia, Astra, Aventis and Bristol-Myers Squibb, among other concerns.

Significant events during the fourth quarter

- Updated data from the Phase I/II study with INTUVAX in the treatment of primary liver cancer was submitted three times during the year. In the most recent update on 18 April, data was presented showing that the treatment with INTUVAX increases the frequency of tumour specific CD8+ T cells in the majority of full-treated liver cancer patients, and that this increase directly correlates with prolonged survival.
- On 22 April the State Intellectual Property Office (SIPO) of the People's Republic of China reported that it intends to grant Immunicum's patent application concerning INTUVAX.
- On 2 May Immunicum announced that the Company has applied for listing of the Company's shares on NASDAQ Stockholm's Main Market List. As part of the process, Immunicum's shares have been approved for listing on NASDAQ OMX First North Premier.
- On 17 May a cooperation agreement was reached with Accelovance for clinical development services in order to advance INTUVAX in the U.S. for the treatment of kidney cancer and melanoma.
- Updated follow-up and survival data from the Phase I/II studies with INTUVAX with the treatment of metastatic kidney cancer was submitted on three instances. In the latest update on 13 June, it was found that the results show an ongoing and extended median survival rate that has more than doubled for the patient group overall, and presently the ongoing extended median survival of rate patients with a poor prognosis has more than tripled.
- In June, Immunicum's concluded its preferential rights share issue with the utilisation of the over-subscription issue. Immunicum thus raised approximately SEK 128 million (before share issue costs).
- On 23 June, the Company announced its preliminary plan for the implementation of two separate clinical trials with INTUVAX® with the treatment of advanced melanoma in combination with immune checkpoint inhibitors, a first-line treatment, and the other in a second-line treatment, in the U.S. and Sweden respectively.

Significant events after the closing of the financial year

- Peter Suenaert, MD, Ph.D., was recruited in July to become Immunicum's first Chief Medical Officer (CMO).
- On 22 July, Immunicum filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) in the United States. The application concerns an authorisation to treat kidney cancer patients in the U.S. with Immunicum's cancer immune activators, INTUVAX®, in the Company's ongoing Phase II study, known as the MERECA study (MEtastatic REnal cell CArcinoma).
- On 26 July it was announced that the Chinese State Intellectual Property Office (SIPO) intends to grant approval to the patent application pertaining to Immunicum's CD70 technology.

A few words from the CEO

With the great progress we have reported during the financial year, Immunicum made it clear that we can play an important role in the development of next-generation treatment cancer therapies. The primary focus is on clinical trials with INTUVAX.

During the financial year, we have been able to report promising overall survival data from our clinical trials of INTUVAX, both for primary liver cancer and metastatic kidney cancer. At the most recent update in June 2016, the follow-up data from the completed renal cancer study showed concerning a continuing more than doubled prolonged median survival rate for the entire patient group and a continuing more than tripled prolonged median survival rate for patients with a poor prognosis. In the study with patients with primary liver cancer, we have shown that treatment with INTUVAX increases the frequency of tumour-specific CD8+ T cells in the blood of the majority of the fully-treated liver cancer patients, and that this appears to be associated with prolonged survival.

We have also been approved and initiated treatment of a further six liver cancer patients who are receiving INTUVAX as first-line therapy in combination with standard treatment that can remove immunosuppression. The 11 patients in the first part of the study were treated with INTUVAX monotherapy when they no longer responded to approved first-line therapy.

In December, we received the go-ahead to launch our fourth clinical trials with INTUVAX. The study includes 12 patients with gastrointestinal stromal tumours (GIST), at the Karolinska University Hospital in Stockholm. The study has commenced, but no data reporting has occurred so far. If the study delivers positive data, we will seek an orphan medicinal product for human use designation for INTUVAX in the treatment of GIST.

Our ongoing Phase II-study with the treatment of kidney cancer patients – MERECA has commenced patient recruitment in Europe and we filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in late July 2016 where we hope to receive approval to also treat kidney cancer patients in the U.S. with INTUVAX. The FDA has asked for more time to evaluate the application, which is standard procedure in these processes, and we look forward to receiving a positive response shortly.

The MERECA study has been delayed by approximately 9 months due to an extensive transfer of the production process to a larger GMP facility in Germany, our successful efforts to develop a much simpler product that is easier for the hospitals to manage, and the protracted evaluation process of the applications for start of clinical trials in most of the European countries. The latter is due to that INTUVAX is an entirely new type of advanced cell therapy, which therefore requires special evaluation and assessment by the public authorities.

"In December we received the go-ahead to launch our fourth clinical trial with INTUVAX."

Today we have a received approval to commence the recruitment in seven of the eight planned countries in Europe and anticipate being able to commence recruiting in the U.S. within a year, provided that we have our IND application approved. Then we also hope to be able to submit aggregated information regarding the scope of the MERECA study and its schedule.

Furthermore, we also plan to conduct two melanoma studies in the United States and Sweden with INTUVAX in combination with various different immune checkpoint inhibitors. The preliminary plan for these studies has not yet been finalised, therefore changes may be made, based on among other things the agencies' responses after the applications have been submitted.

Our focus is on the implementation of the planned studies with INTUVAX, but we also see great potential in our two other technology platforms, CD70 and the adenovirus vector. For these projects, development work is ongoing in cooperation with Professor Magnus Essand and his team at the Uppsala University.

Before the summer, a successful preferential rights share issue was implemented which raised SEK 128 million (before share issue costs). In order to increase the possibilities of broadening our shareholder base plus to further facilitate the Company's financing in the future, we have applied to have Immunicum's shares listed on the NASDAQ Stockholm Main Market List. In view of that the Nominating Committee has nominated three new board members – Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm – for election at the Annual General Meeting in October, a listing on the Main Market List would be able to occur at the soonest in early 2017. As part of the process to be listed on the Main Market List, Immunicum's shares have been approved for listing on NASDAQ OMX First North Premier.

Immunicum's organisation has been strengthened in several respects over the course of the financial year. In March, the Company's Scientific Advisory Board was expanded with Anders Öhlén, M.D., Ph.D., and in July Peter Suenaert, M.D., Ph.D., was recruited as Chief Medical Officer. The organisation has been further strengthened by recruiting new staff with a focus on the implementation of our comprehensive clinical programmes as well as via an increased focus on investor relations. At the Annual General Meeting in December 2015, Magnus Persson was elected as a new member of Immunicum's Board of Directors.

Efforts to secure the future intellectual property rights continues, and during the financial year we have had several patents for INTUVAX and CD70 approved in China, Japan and Europe.

During this financial year, we were able to achieve quite a bit thanks to a sharp and dedicated team. I would also like to take this opportunity to thank you for the strong support that our shareholders have shown, and look forward with confidence to the coming year.

Jamal El-Mosleh
CEO

Financial information

FINANCIAL RESULTS

Operating profit/loss amounted to TSEK -43,643 (TSEK -36,404), and reported profit/loss, amounted to TSEK -43,923 (TSEK -35,615), of which from the fourth quarter TSEK -15,068 (TSEK -8,230) and TSEK -15,018 (TSEK -7,804) respectively. Earnings per share before dilution amounted to SEK -2.18 (-1.78), of which SEK -0.74 (-0.39) was attributable to the fourth quarter. Earnings per share after dilution amounted to SEK -2.01 (-1.78), of which SEK -0.69 (-0.39) was attributable to the fourth quarter.

The Company's operating expenses have increased as compared to the previous year, due to increased costs for clinical trials. The fact that we have a greater number of employees has resulted in higher costs for personnel.

CASH FLOW

The cash flow which was employed for the operating activities amounted to TSEK -40,229 (TSEK -40,102), of which TSEK -15,342 (TSEK -8,033) was during the fourth quarter. Cash flow from investment activities amounted to TSEK 25,651 (TSEK -35,000), of which 0 (0) relates to the fourth quarter, due to the change in the holdings of unit trust/mutual fund investments. Cash flow from financing activities amounted to TSEK 101,788 (0), of which TSEK 101,788 (0) was from the fourth quarter, as the Company raised SEK 114.0 million from the new share issue (before share issue costs, which were SEK 12.2 million). After the close of the reporting period, the Company received an additional SEK 16.7 million pertaining to the subscribed capital which had not yet been paid in at the close of the reporting period.

The Company's liquid assets at 30 June 2016 amounted to TSEK 119,949 (TSEK 32,738). In addition, TSEK 9,493 (TSEK 35,427) was invested in a unit trust at a major Swedish bank. Total thus cash and cash equivalents plus the funds invested in unit trusts amounted to TSEK 129,442 (TSEK 68,165) at the end of the period.

SHAREHOLDERS' EQUITY

Total shareholders' equity at 30 June 2016 amounted to TSEK 139,180 (TSEK 64,627), which corresponds to SEK 5.36.(3.23) per share. The Company's equity ratio at the end of the period was 90.2% (91.0%).

THE ISSUANCE OF NEW SHARES

The subscription period for the 2012/2016 warrants programme concluded on 31 March 2016. A total of 130,000 new shares were subscribed for, of a total of 600,000 potential shares. The subscription price was SEK 24 per share. Via this new share issue, Immunicum was provided with SEK 3.1 million (before share issue costs). The share capital increased by SEK 6,500.

On 18 May 2016, an Extraordinary Meeting of Shareholders resolved to implement a new share issue with preferential rights for existing shareholders in the total amount of 5,040,000 shares at a subscription price of SEK 22 per share. The Extraordinary Meeting of Shareholders also authorised the Board of Directors to conduct a private placement (in the event the preferential rights issue is fully subscribed) of a maximum of 910,000 shares at the identical subscription price. The subscription period ended on 14 June 2016. The final result showed that a total of 4,110,869 shares were subscribed for based on subscription rights, representing approximately 82% of the preferential rights share issue. In addition, applications were received for the subscription of shares without subscription rights for a total of 1,687,672 shares, representing approximately 33% of the preferential rights share issue. The degree of over-subscription was approximately 15%. Via the issuance of these new shares, Immunicum was received a capital injection of SEK 127.6 million (before share issue costs). The share capital will increase by SEK 289,927.

Other information

THE IMMUNICUM SHARE

The shares have been trading on NASDAQ First North under the ticker symbol IMMU, with the ISIN code SE0005003654 since 22 April 2013. As of 4 May 2016, the Company's shares have been listed on the First North Premier segment.

NUMBER OF SHARES

The number of shares in the Company as of 30 June 2016 amounts to 24,270,869 (20,030,000). At that time there was a preferential rights share issue underway and an oversubscription of new shares relating to 1,687,672 shares. With the registration in full in July 2016 of the shares from the new share issue, the total number of shares will amount to 25,958,541.

SHAREHOLDERS ON 29/07/2016

SHAREHOLDER	SHARES	SHARE OF CAPITAL/ VOTES
Holger Blomstrand Byggnads AB	2,975,386	11.5 %
Loggen Invest AB	2,750,000	10.6 %
Försäkringsaktiebolaget, Avanza Pension	2,031,712	7.8 %
Swedbank Robur Fonder AB	1,562,500	6.0 %
Nordnet Pensionsförsäkring AB	649,912	2.5 %
Alex Karlsson-Parra incl. related parties	612,726	2.4 %
Bengt Andersson	557,939	2.1 %
Jamal El-Mosleh	393,000	1.5 %
Mats Dahlgren	380,000	1.5 %
UBS Switzerland AG	362,644	1.4 %
Total, ten largest shareholders	**12,275,819**	**47.3 %**
Other shareholders	13,682,722	52.7 %
TOTAL	**25,958,541**	**100.0 %**

DIVIDENDS

The Board of Directors and the CEO propose that no dividend be paid for the 2015/2016 financial year.

INCENTIVE PROGRAMME

There are currently no outstanding warrants, options, or other equity-related incentive programmes in the Company.

PERSONNEL ON STAFF

Immunicum has chosen to conduct its business operations with a minimal number of employees on staff supplemented by consultants, in order to maintain flexibility and cost effectiveness. As of 30 June 2016, the Company had 8 (5) direct employees, of whom 5 (2) were women and 3 (3) men.

INFORMATION ON TRANSACTIONS WITH CLOSELY RELATED PARTIES

No transactions that significantly affected the Company's earnings and financial position have been carried out with closely related parties during the period.

PROSPECTS, RISKS AND UNCERTAINTIES

Immunicum is a research and development company that still is in its early stages. The Company has not generated any revenues historically and is not expected to do so in the short term. The Company's candidates for vaccines and technology platforms are dependent on research and development and may be delayed and/or incur greater costs. The Company is dependent upon its ability to enter into licensing agreements and joint collaboration agreements, as well as dependent on a large number of approvals and remuneration systems and the related laws, regulations, decisions and practices (which may change). In addition, the Company is also dependent upon intellectual property rights, including know-how and trade secrets.

For a more detailed description of the material risk factors, please refer to Immunicum's most recent prospectus (Prospectus for the Preferential Rights Share Issue, 2016) which can be downloaded at the following link:

http://immunicum.se/investerare-se/prospekt-och-memorandum/

NOMINATION COMMITTEE – 2016 ANNUAL GENERAL MEETING

Immunicum's Nomination Committee for the 2016 Annual General Meeting consists of:

- Evert Carlsson, Chair of the Committee (appointed by Swedbank Robur Fonder AB)
- Martin Lindström (appointed by Loggen Invest AB)
- Bengt Andersson (appointed by Bengt Andersson)
- Mats Dahlgren (appointed by Mats Dahlgren)
- Agneta Edberg, Chair of the Board of Directors

The appointments were made according to the principles for appointing the Nomination Committee established at the Annual General Meeting of Immunicum AB on 3 December 2015.

FINANCIAL CALENDAR

Annual Report 2015/2016	30 September 2016
Annual General Meeting	26 October 2016
Interim Report July 2016 - September 2016	18 November 2016
Interim Report July 2016 - December 2016	17 February 2017
Interim Report July 2016 - March 2017	19 May 2017
Year-End Report 2016/2017	18 August 2017

CERTIFIED ADVISER

Immunicum's Certified Adviser is Redeye AB.

Statement of Comprehensive Income, Summary

AMOUNTS IN SEK	01/04/2016 - 30/06/2016	01/04/2015 - 30/06/2015	01/07/2015 - 30/06/2016	01/07/2014 - 30/06/2015
Other operating income	-	-	-	160,000
	-	-	-	160,000
OPERATING EXPENSES				
Other external costs	-11,723,734	-6,847,195	-33,377,951	-30,638,046
Personnel costs	-3,129,325	-1,406,870	-9,965,352	-5,776,020
Depreciation of tangible fixed assets	-20,679	27,592	-82,714	-83,806
Other operating expenses	-194,296	-3,778	-216,731	-65,967
Operating profit/loss	**-15,068,034**	**-8,230,251**	**-43,642,748**	**-36,403,839**
INCOME FROM FINANCIAL ITEMS				
Interest income and similar items	72	435,807	19,677	813,037
Interest expense and similar items	49,846	-9,351	-299,814	-23,821
Profit/loss after financial items	**-15,018,116**	**-7,803,795**	**-43,922,885**	**-35,614,623**
TOTAL PROFIT/LOSS BEFORE TAXES	**-15,018,116**	**-7,803,795**	**-43,922,885**	**-35,614,623**
Income tax expense on the year's net income	-	-	-	-
PROFIT/LOSS FOR THE PERIOD	**-15,018,116**	**-7,803,795**	**-43,922,885**	**-35,614,623**

The statement of overall financial results is consistent with the financial results for the period.

Earnings per share, before and after dilution	-0.74	-0.39	-2.18	-1.78

Balance Sheet, Summary

AMOUNTS IN SEK	30/06/2016	30/06/2015
ASSETS		
Subscribed capital unpaid	16,687,902	-
FIXED ASSETS		
Tangible assets		
Equipment	180,793	263,507
Total tangible assets	**180,793**	**263,507**
Financial assets		
Other securities held as fixed assets	1,000	1,000
Total financial assets	**1,000**	**1,000**
TOTAL FIXED ASSETS	**181,793**	**264,507**
CURRENT ASSETS		
Current receivables		
Tax credits and related receivables	101,285	-
Other receivables	3,640,900	1,232,222
Prepaid expenses and accrued income	4,185,405	1,372,095
Total current receivables	**7,927,590**	**2,604,317**
Investments	**9,493,383**	**35,426,626**
Cash and bank balances	**119,948,858**	**32,738,441**
TOTAL CURRENT ASSETS	**137,369,831**	**70,769,384**
TOTAL ASSETS	**154,239,526**	**71,033,891**

Balance Sheet, Summary, cont'd

AMOUNTS IN SEK	30/06/2016	30/06/2015
SHAREHOLDERS' EQUITY AND LIABILITIES		
SHAREHOLDERS' EQUITY		
Restricted equity		
Share capital	1,213,543	1,001,500
New share issues in progress	84,384	-
Total restricted equity	**1,297,927**	**1,001,500**
Unrestricted equity		
Share premium reserve	252,535,222	134,355,491
Retained earnings	-70,730,294	-35,115,671
Profit/loss for the period	-43,922,885	-35,614,623
Total unrestricted equity	**137,882,043**	**63,625,197**
TOTAL SHAREHOLDER EQUITY	**139,179,970**	**64,626,697**
LIABILITIES		
Long-term liabilities		
Other long-term liabilities	850,000	850,000
Total long-term liabilities	**850,000**	**850,000**
Current liabilities		
Accounts payable	5,043,606	2,453,352
Other liabilities	199,826	103,919
Accrued expenses and deferred income	8,966,124	2,999,923
Total current liabilities	**14,209,556**	**5,557,194**
TOTAL LIABILITIES	**15,059,556**	**6,407,194**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	**154,239,526**	**71,033,891**
Pledged assets	565,537	465,478
Contingent liabilities	None	None

Report on Changes in Shareholders' Equity, Summary

AMOUNTS IN SEK	Share capital	Share premium reserve	Retained earnings	Net profit/loss before for the year	Total
Opening shareholders' equity 01/07/2014	1,001,500	134,355,491	-18,940,635	-16,175,036	100,241,320
Transfer of prior years' profit/loss			-16,175,036	16,175,036	
Profit/loss for the period				-35,614,623	-35,614,623
Shareholders' equity 30/06/2015	1,001,500	134,355,491	-35,115,671	-35,614,623	64,626,697
Opening shareholder' equity 01/07/2015	1,001,500	134,355,491	-35,115,671	-35,614,623	64,626,697
The issuance of new shares	212,043	93,347,075			93,559,118
Costs attributable to the new share issues		-12,211,744			-12,211,744
New share issues in progress	84,384	37,044,400			37,128,784
Transfer of prior years' profit/loss			-35,614,623	35,614,623	
Profit/loss for the period				-43,922,885	-43,922,885
Shareholders' equity 30/06/2016	1,297,927	252,535,222	-70,730,294	-43,922,885	139,179,970

Cash Flow Statement, Summary

AMOUNTS IN SEK	01/04/2016 - 30/06/2016	01/04/2015 - 30/06/2015	01/07/2015 - 30/06/2016	01/07/2014 - 30/06/2015
OPERATING ACTIVITIES				
Operating profit/loss before financial items	-15,068,034	-8,230,251	-43,642,748	-36,403,839
Depreciation, amortisation and other non-cash items	20,679	294,208	82,714	83,806
Interest income received	72	9,181	19,677	386,411
Interest expense paid	-8,642	-9,351	-17,334	-23,821
Cash flow from operating activities before changes in working capital	**-15,055,925**	**-7,936,213**	**-43,557,691**	**-35,957,443**
Increase/decrease in other current term receivables	-5,552,854	-433,211	-5,323,273	-1,258,186
Increase/decrease in accounts payable	3,470,639	72,395	2,590,254	1,430,468
Increase/decrease in other short-term liabilities	1,795,719	264,007	6,062,108	-4,316,966
Changes in working capital	**-286,496**	**-96,809**	**3,329,089**	**-4,144,684**
CASH FLOW FROM OPERATING ACTIVITIES	**-15,342,421**	**-8,033,022**	**-40,228,602**	**-40,102,127**
INVESTMENT ACTIVITIES				
Acquisition of short term investments	-	-	-	-35,000,000
Sale of investments	-	-	25,650,763	-
CASH FLOW FROM INVESTMENT ACTIVITIES	**-**	**-**	**25,650,763**	**-35,000,000**
FINANCING ACTIVITIES				
The issuance of new shares	114,000,000	-	114,000,000	-
Share issue costs	-12,211,744	-	-12,211,744	-
CASH FLOW FROM FINANCING ACTIVITIES	**101,788,256**	**-**	**101,788,256**	**-**
Cash flow for the year	86,445,835	-8,033,022	87,210,417	-75,102,127
Cash and cash equivalents at the beginning of the period	33,503,023	40,771,463	32,738,441	107,840,568
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**119,948,858**	**32,738,441**	**119,948,858**	**32,738,441**

Note 1 Accounting Policies

The Company prepares its interim reports in accordance with IAS 34 with regard to the exceptions from and additions to IFRS which are listed in RFR2 and the Swedish Annual Accounts Act. The Company is not a part of any group of companies, which is why a full IFRS reporting will not be applicable. The accounting principles and calculation methods remain unchanged from those applied in the Annual Report for 2014/2015.

Note 2 Fair Value of Financial Instruments

The carrying amount is assessed to be a reasonable estimate of the fair value for the financial instruments held by the Company. The Company's holdings of short-term investments are valued in accordance with the principle of lower of cost or net realisable value.

Gothenburg, 30 August 2016

Immunicum AB (publ)

Agneta Edberg
CHAIR OF THE BOARD OF DIRECTORS

Bengt Furberg
MEMBER OF THE BOARD

Martin Lindström
MEMBER OF THE BOARD

Magnus Nilsson
MEMBER OF THE BOARD

Magnus Persson
MEMBER OF THE BOARD

Jamal El-Mosleh
CEO

FOR FURTHER INFORMATION, PLEASE CONTACT:

Jamal El-Mosleh, CEO
Grafiska Vägen 2
412 63 Gothenburg

031-41 50 52

info@immunicum.com

www.immunicum.com

Organisation number: 556629-1786

This information is the information that the Company is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, , via the above contact person, on 31 August 2016 at 08:30.



CONTACT
+46 (0)31-41 50 52
info@immunicum.com
www.immunicum.com

OFFICES
Grafiska vägen 2
412 63, Göteborg, Sweden